Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: Improvement in hemodynamic and metabolic profile

[1]  L. Opie,et al.  Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. , 1992, Journal of the American College of Cardiology.

[2]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[3]  G. Curfman.  Inotropic therapy for heart failure--an unfulfilled promise. , 1991, The New England journal of medicine.

[4]  T. Hedner,et al.  Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. , 1991, Journal of the American College of Cardiology.

[5]  F. Fallani,et al.  Myocardial metabolic and hemodynamic effects of a sustained intravenous infusion of nifedipine with and without metoprolol in patients with unstable angina. , 1991, American Heart Journal.

[6]  G. Hasenfuss,et al.  Myocardial energetics in dilated cardiomyopathy , 1990, Clinical cardiology.

[7]  G. Belz,et al.  The Effects of Oral Enoximone on Cardiac Performance, Calf Arterial Blood Flow, and Constrictor Effects of Norepinephrine Infused Into Hand Veins in Humans , 1990, Journal of cardiovascular pharmacology.

[8]  S. Mörner,et al.  Analysis of the Inotropic Mechanism of Enoximone in Guinea Pig Ventricular Muscle , 1990, Journal of cardiovascular pharmacology.

[9]  H. Herrmann,et al.  Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. , 1990, Circulation.

[10]  P. Grayburn,et al.  Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. , 1990, Circulation.

[11]  A. Katz.  Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. , 1990, The New England journal of medicine.

[12]  T. Meinertz,et al.  Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone. , 1989, Circulation.

[13]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.

[14]  M. Packer.  Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. , 1989, The American journal of cardiology.

[15]  G. Hasenfuss,et al.  Influence of Enoximone on Mechanics and Energetics of Right Ventricular Guinea Pig Papillary Muscles , 1989, Journal of cardiovascular pharmacology.

[16]  C. Leier,et al.  Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study. , 1988, American heart journal.

[17]  R. O'rourke,et al.  Hemodynamic Effects of Prolonged Intravenous Therapy with Enoximone in Patients with Severe Congestive Heart Failure , 1988, Journal of cardiovascular pharmacology.

[18]  T. Meinertz,et al.  Cardiac energetics after intravenous enoximone in idiopathic dilated cardiomyopathy. , 1987, The American journal of cardiology.

[19]  H. Herrmann,et al.  Inotropic effect of enoximone in patients with severe heart failure: demonstration by left ventricular end-systolic pressure-volume analysis. , 1987, Journal of the American College of Cardiology.

[20]  T. Bashore,et al.  Histologic and biochemical correlates of left ventricular chamber dynamics in man. , 1987, Journal of the American College of Cardiology.

[21]  A. Hakki,et al.  Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. , 1986, The American journal of cardiology.

[22]  Katz Am.  Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. , 1986 .

[23]  P. Cannon,et al.  Left ventricular mechanical efficiency in coronary artery disease. , 1986, Journal of the American College of Cardiology.

[24]  A. Katz.  Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. , 1986, Circulation.

[25]  F. Shellock,et al.  Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. , 1985, American heart journal.

[26]  W. Parmley,et al.  Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure. , 1985, Journal of the American College of Cardiology.

[27]  W. Laskey,et al.  Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure. , 1984, Journal of the American College of Cardiology.

[28]  W. Parmley,et al.  Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients. , 1984, Journal of the American College of Cardiology.

[29]  F. Shellock,et al.  Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure. , 1984, American heart journal.

[30]  J. F. Lang,et al.  Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. , 1984, The American journal of cardiology.

[31]  M. Crawford,et al.  Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance. , 1984, The American journal of cardiology.

[32]  R. Mates,et al.  Preload-induced alterations in capacitance-free diastolic pressure-flow relationship. , 1984, The American journal of physiology.

[33]  P. Reddy,et al.  The Acute Hemodynamic Effects of a New Agent, MDL 17,043, in the Treatment of Congestive Heart Failure , 1983, Circulation.

[34]  F. Waagstein,et al.  Beta-blockers in dilated cardiomyopathies: they work. , 1983, European heart journal.

[35]  R. Magorien,et al.  The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. , 1983, American heart journal.

[36]  R. C. Dage,et al.  Biochemical Studies on the Mechanism of Cardiotonic Activity of MDL 17,043 , 1982, Journal of cardiovascular pharmacology.

[37]  Stanton A. Glantz,et al.  Primer of biostatistics : statistical software program version 6.0 , 1981 .

[38]  E. Braunwald,et al.  Effects of Amrinone on Myocardial Energy Metabolism and Hemodynamics in Patients with Severe Congestive Heart Failure Due to Coronary Artery Disease , 1980, Circulation.

[39]  Lee Jc,et al.  Cyclic AMP and the pathogenesis of myocardial injury. , 1980 .

[40]  S. Downing,et al.  Cyclic AMP and the pathogenesis of myocardial injury. , 1980, Research communications in chemical pathology and pharmacology.

[41]  H. Ikram,et al.  Haemodynamic effects of acute beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1979, British heart journal.

[42]  F. Klocke,et al.  Coronary blood flow in man. , 1976, Progress in cardiovascular diseases.

[43]  J R Neely,et al.  Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. , 1974, Annual review of physiology.

[44]  O. Mjøs.  Effect of inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol. , 1971, The Journal of clinical investigation.

[45]  H. Swan,et al.  Measurement of Coronary Sinus Blood Flow by Continuous Thermodilution in Man , 1971, Circulation.

[46]  P. Martorana.  The role of cyclic AMP in isoprenaline‐induced cardiac necroses in the rat * , 1971, The Journal of pharmacy and pharmacology.

[47]  H. Levine,et al.  Patterns of human myocardial oxygen extraction during rest and exercise. , 1962, The Journal of clinical investigation.

[48]  R. Furchgott,et al.  High Energy Phosphates and the Force of Contraction of Cardiac Muscle , 1961, Circulation.

[49]  S. Kety,et al.  The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man , 1949 .